scispace - formally typeset
E

Erik S. Wallen

Researcher at University of New Mexico

Publications -  19
Citations -  376

Erik S. Wallen is an academic researcher from University of New Mexico. The author has contributed to research in topics: Heat shock protein & Hyperthermia. The author has an hindex of 10, co-authored 18 publications receiving 366 citations.

Papers
More filters
Journal ArticleDOI

The function of annotations in the comprehension of scientific texts: Cognitive load effects and the impact of verbal ability

TL;DR: This article investigated the effectiveness of three types of annotations on three learning outcome measures: recall of facts, comprehension of the text, and mental model construction, and found that having multiple types of annotation resulted in a higher cognitive load that resulted in lower performance.
Journal ArticleDOI

Computer-based training for safety: comparing methods with older and younger workers.

TL;DR: Computer-based training with pictures and audio narration may be beneficial for workers over 45 years of age and should be designed and selected based on their ability to effectively train older as well as younger learners.
Journal ArticleDOI

Effects of combined treatment of chemotherapeutics and hyperthermia on survival and the regulation of heat shock proteins in Dunning R3327 prostate carcinoma cells

TL;DR: The study of HSP regulation is important in the establishment of effective schedules in multimodal treatment strategies, given the role of heat shock proteins in the development of resistance to subsequent hyperthermic stresses.
Journal ArticleDOI

Heat shock protein 70 and glycoprotein 96 are differentially expressed on the surface of malignant and nonmalignant breast cells.

TL;DR: Surface expression of both glycoprotein 96 and Hsp70 occurs on tumor cells, and this expression correlates with natural killer cell killing of the cells, so these observations may be important in the immune response to tumor cells.
Book ChapterDOI

Heat shock protein (HSP72) surface expression enhances the lysis of a human renal cell carcinoma by IL-2 stimulated NK cells.

TL;DR: Patients with advanced renal cell carcinoma with a poor prognosis due to the failure of this tumor entity to respond to conventional therapeutic approaches such as irradiation or chemotherapy are treated with interleukin-2 based immunotherapy.